title: Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study.
abstract: IFN alpha has both antiviral and immunostimulating properties. The ANRS086 Primoferon A Study evaluated in 12 patients with primary HIV infection the tolerance and efficacy of an early and transient administration of pegylated IFN alpha, in addition to highly active antiretroviral therapy. Tolerance was good, and this regimen allowed the early control of HIV replication and rapid decay of the viral reservoir. These results support the initiation of comparative studies with pegylated INF alpha in primary HIV infection.
authors.affiliation: Service de Médecine Interne et d'Immunologie Clinique, Hôpital Antoine Béclère, Institut Paris-Sud sur les Cytokines, Clamart, France.
authors.forename: D
authors.initials: D
authors.lastname: Emilie
authors.forename: M
authors.initials: M
authors.lastname: Burgard
authors.forename: C
authors.initials: C
authors.lastname: Lascoux-Combe
authors.forename: M
authors.initials: M
authors.lastname: Laughlin
authors.forename: R
authors.initials: R
authors.lastname: Krzysiek
authors.forename: C
authors.initials: C
authors.lastname: Pignon
authors.forename: A
authors.initials: A
authors.lastname: Rudent
authors.forename: J M
authors.initials: JM
authors.lastname: Molina
authors.forename: J M
authors.initials: JM
authors.lastname: Livrozet
authors.forename: F
authors.initials: F
authors.lastname: Souala
authors.forename: G
authors.initials: G
authors.lastname: Chene
authors.forename: L
authors.initials: L
authors.lastname: Grangeot-Keros
authors.forename: P
authors.initials: P
authors.lastname: Galanaud
authors.forename: D
authors.initials: D
authors.lastname: Sereni
authors.forename: C
authors.initials: C
authors.lastname: Rouzioux
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004797:Enzyme-Linked Immunosorbent Assay; D016655:HIV Core Protein p24 / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D014779:Virus Replication
chemical_list: D000998:Antiviral Agents; D016655:HIV Core Protein p24; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a